Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of Your Number one Cake Type - 2Forum Dvorah demands clear support for women in combat as IDF gender debate escalates
- 3New Jordan security fence could be done in early 2028
- 4An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- 5How did Ariana Grande get her Glinda voice? I’m the man behind the magic.
- Scientists map of old Mars river basins for the 1st time. These could be great places to search for ancient life
- Iranian-backed militias escalate in Iraq, targeting Kurdistan Region president Nechirvan Barzani
- 4 astronauts depart ISS, leaving behind just 3 crewmates to staff the orbiting lab
- Ergonomic Office Seats for Work spaces
- The 15 Most Compelling Books in History
- Vote in favor of your Number one Sort of Cap
- Irish defence minister's trip to Lebanon cancelled
- Whale stranded off Germany for days found stuck again
- The Force of Systems administration: Individual Examples of overcoming adversity
